Peter Lamb
YOU?
Author Swipe
View article: Development and application of quality assurance methods for interventions in randomised controlled trials of surgical oncology: the ROMIO study (a comparison of minimally invasive and open oesophagectomy)
Development and application of quality assurance methods for interventions in randomised controlled trials of surgical oncology: the ROMIO study (a comparison of minimally invasive and open oesophagectomy) Open
Introduction Results of RCTs are criticised because the quality assurance (QA) of surgical interventions is not considered. This is particularly true in cancer trials, because higher standards of surgery may confer more favourable outcomes…
View article: Global Variations in Practices after Bariatric and Metabolic Surgery; the PARTNER Study
Global Variations in Practices after Bariatric and Metabolic Surgery; the PARTNER Study Open
The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity…
View article: Intravenous Iron Infusion in the Treatment of Iron Deficiency Anaemia Following Bariatric and Metabolic Surgery and Correlation with Gynaecological Disorders: Retrospective Review of Experience from a Tertiary Centre
Intravenous Iron Infusion in the Treatment of Iron Deficiency Anaemia Following Bariatric and Metabolic Surgery and Correlation with Gynaecological Disorders: Retrospective Review of Experience from a Tertiary Centre Open
Background and Objectives: Iron deficiency anaemia (IDA) is a common consequence of bariatric and metabolic surgery (BMS). Women are at higher risk, and some patients cannot tolerate oral iron. This study aimed to report the demographics o…
View article: Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study Open
Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its…
View article: The Role of Preoperative Weight Loss Interventions on Long-Term Bariatric Surgery Outcomes: A Systematic Review
The Role of Preoperative Weight Loss Interventions on Long-Term Bariatric Surgery Outcomes: A Systematic Review Open
Background/Objectives: The percentage of the world’s population with Class II obesity (body mass index (BMI) ≥ 35) and above is increasing annually. Bariatric (elective weight-loss) surgery is performed for less than one percent of eligibl…
View article: An international Delphi consensus on patient preparation for metabolic and bariatric surgery
An international Delphi consensus on patient preparation for metabolic and bariatric surgery Open
Summary Global obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m 2 ), is performed globally over 500 000 times annually, offering …
View article: Surgical treatment of Boerhaave syndrome in the past, present and future: updated results of a specialised surgical unit
Surgical treatment of Boerhaave syndrome in the past, present and future: updated results of a specialised surgical unit Open
Early and aggressive management of spontaneous oesophageal rupture ameliorates the postoperative recovery and prognosis. The surgical results of our unit were found comparable to the previous decade in the population of patients who were t…
View article: Data from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Data from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and the TAM family of kinases TYRO3, AXL and MER. Presented here is a preclinical evaluation of XL09…
View article: Sex-related differences in oncologic outcomes, operative complications and health-related quality of life after curative-intent oesophageal cancer treatment: multicentre retrospective analysis
Sex-related differences in oncologic outcomes, operative complications and health-related quality of life after curative-intent oesophageal cancer treatment: multicentre retrospective analysis Open
Background Oesophageal cancer, in particular adenocarcinoma, has a strong male predominance. However, the impact of patient sex on operative and oncologic outcomes and recovery of health-related quality of life is poorly documented, and wa…
View article: Laparoscopic or open abdominal surgery with thoracotomy for patients with oesophageal cancer: ROMIO randomized clinical trial
Laparoscopic or open abdominal surgery with thoracotomy for patients with oesophageal cancer: ROMIO randomized clinical trial Open
Objective This study investigated if hybrid oesophagectomy with minimally invasive gastric mobilization and thoracotomy enabled faster recovery than open surgery. Methods In eight UK centres, this pragmatic RCT recruited patients for oesop…
View article: OGC P58 Clinical Rationale for Staging Laparoscopy in Oesophagogastric cancers: A high-volume tertiary centre study
OGC P58 Clinical Rationale for Staging Laparoscopy in Oesophagogastric cancers: A high-volume tertiary centre study Open
Background Oesophagagogastric cancers are characterised by their propensity to spread to the locoregional lymph nodes or to distant sites by transcoelomic migration. Accurate staging is imperative to select patients for treatment according…
View article: 373. THE PROGNOSTIC IMPACT OF TIME DELAYS IN OESOPHAGEAL CANCER SURGERY: 10-YEAR EXPERIENCE OF A HIGH-VOLUME CENTRE
373. THE PROGNOSTIC IMPACT OF TIME DELAYS IN OESOPHAGEAL CANCER SURGERY: 10-YEAR EXPERIENCE OF A HIGH-VOLUME CENTRE Open
Background Over the last twenty years, treatment of oesophageal cancer has changed towards a multimodal approach to achieve better clinical outcomes. Detailed staging paradigms and neoadjuvant treatment have resulted in a longer time perio…
View article: Patient Pathways to Bariatric Surgery
Patient Pathways to Bariatric Surgery Open
Introduction: Bariatric surgery is an accepted treatment worldwide for patients with obesity due to its proven metabolic effects. However, there are variations worldwide in clinical criteria that must be met to qualify for surgery. This st…
View article: Data from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Data from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway Open
Activation of the PI3K (phosphoinositide 3-kinase) pathway is a frequent occurrence in human tumors and is thought to promote growth, survival, and resistance to diverse therapies. Here, we report pharmacologic characterization of the pyri…
View article: Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Dysregulation of PI3K/PTEN pathway components, resulting in hyperactivated PI3K signaling, is frequently observed in various cancers and correlates with tumor growth and survival. Resistance to a variety of anticancer therapies, including …
View article: Suppl Figure 4 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Suppl Figure 4 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
Suppl Figure 4
View article: Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Effects of XL147 on PI3K Pathway Signaling in A549, MDA-MB-468 and LS174T cells.
View article: Suppl Figure 2 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Suppl Figure 2 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
Suppl Figure 2
View article: Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Effects of XL147 on PI3K Signaling Pathway in OVCAR-3 and U87-MG cells.
View article: Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway Open
PDF - 1553K, Supplemental Figure S1: Effects of XL765 on PI3K Signaling Pathway in EGF-Stimulated PC-3 Cells. Supplemental Figure S2: Effects of XL765 on PI3K Signaling Pathway in OVCAR-3 and U87 MG cells. Supplemental Figure S3: Effects o…
View article: Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Effects of XL147 on PI3K Pathway Signaling in A549, MDA-MB-468 and LS174T cells.
View article: Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Dose-response relationships for inhibition of PI3K pathway signaling by XL147 in tumors.
View article: Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Body weight plots for efficacy studies shown in figures 5 and 6.
View article: Suppl Figure 4 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Suppl Figure 4 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
Suppl Figure 4
View article: Suppl Figure 1 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Suppl Figure 1 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
Suppl Figure 1
View article: Suppl Figure 2 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Suppl Figure 2 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Open
Suppl Figure 2
View article: Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models Open
Dysregulation of PI3K/PTEN pathway components, resulting in hyperactivated PI3K signaling, is frequently observed in various cancers and correlates with tumor growth and survival. Resistance to a variety of anticancer therapies, including …